Across TCGA pan-cancer cohorts, ATXN1L mass-spec protein differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of ATXN1L’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where ATXN1L mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types ATXN1L is over-expressed in tumor, although a few such as HNSC and LSCC show the opposite, repressed pattern.

HNSC, LSCC, and CCRCC are the cancer types where ATXN1L tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ATXN1L mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	Male	All	−0.273	<.001	8	view →
LSCC	All	III,IV	−0.200	<.001	6	view →
CCRCC	All	II,III,IV	−0.094	.001	4	view →
LUAD	All	All	−0.091	<.001	3	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: ATXN1L RNA expression & survival · all ATXN1L data types